Technical Analysis for TCON - TRACON Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 1.43 -6.54% -0.10
TCON closed down 6.54 percent on Friday, May 17, 2024, on 38 percent of normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%

   Recent Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

TRACON Pharmaceuticals, Inc. Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focused on the development and commercialization of novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. Its lead product candidate is TRC105, which is in Phase II clinical trials for oncology indications, including soft tissue sarcoma, renal cell carcinoma, glioblastoma, and hepatocellular carcinoma. The company is planning for clinical trials of TRC105, including a Phase II clinical trial in patients with breast cancer and hepatocellular carcinoma, a Phase I clinical trial in patients with colorectal cancer, and a Phase I clinical trial in patients with lung cancer, as well as conducting preclinical studies of TRC105 in AMD. In addition, the company product candidates comprise TRC205, an anti-endoglin antibody that is in preclinical stage for the treatment of fibrotic diseases; and TRC102, a small molecule, which is in clinical development for the treatment of lung cancer and glioblastoma. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Drugs Clinical Development Breast Cancer Clinical Trial Treatment Of Breast Cancer Colorectal Cancer Blastoma Macular Degeneration Glioblastoma Lung Cancer Sarcoma Carcinoma Targeted Therapy Hepatocellular Carcinoma Age Related Macular Degeneration Renal Cell Carcinoma Soft Tissue Sarcoma Fibrotic Disease Therapeutics For Cancer Transgene Sa

Is TCON a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.746
52 Week Low 1.4201
Average Volume 318,448
200-Day Moving Average 4.06
50-Day Moving Average 4.29
20-Day Moving Average 1.79
10-Day Moving Average 1.77
Average True Range 0.38
RSI (14) 29.08
ADX 17.0
+DI 18.45
-DI 32.41
Chandelier Exit (Long, 3 ATRs) 1.19
Chandelier Exit (Short, 3 ATRs) 2.57
Upper Bollinger Bands 2.07
Lower Bollinger Band 1.52
Percent B (%b) -0.17
BandWidth 30.43
MACD Line -0.54
MACD Signal Line -0.66
MACD Histogram 0.1152
Fundamentals Value
Market Cap 44.54 Million
Num Shares 31.1 Million
EPS -0.44
Price-to-Earnings (P/E) Ratio -3.25
Price-to-Sales 0.71
Price-to-Book 11.83
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.67
Resistance 3 (R3) 1.69 1.64 1.63
Resistance 2 (R2) 1.64 1.58 1.62 1.62
Resistance 1 (R1) 1.53 1.54 1.51 1.51 1.60
Pivot Point 1.48 1.48 1.46 1.47 1.48
Support 1 (S1) 1.37 1.42 1.35 1.35 1.26
Support 2 (S2) 1.32 1.38 1.31 1.24
Support 3 (S3) 1.21 1.32 1.23
Support 4 (S4) 1.19